Published in Blood on September 01, 1999
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol (2011) 2.34
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag (2008) 1.59
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A (2000) 1.09
Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am (2010) 0.90
Development of an effective therapy for chronic myelogenous leukemia. Cancer J (2011) 0.87
Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis. BMC Health Serv Res (2012) 0.84
Recommendations of the canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol (2006) 0.84
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol (2013) 0.82
Is imatinib still the best choice as first-line oral TKI. South Asian J Cancer (2014) 0.81
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr (2003) 0.79
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget (2015) 0.77
Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. J Mol Diagn (2002) 0.76
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. PLoS One (2017) 0.75
Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia. Case Rep Hematol (2015) 0.75
Nanotechnology applications in hematological malignancies (Review). Oncol Rep (2015) 0.75
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia. Korean J Pediatr (2013) 0.75
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget (2016) 0.75
First-line treatment of chronic myeloid leukaemia. Ther Adv Hematol (2010) 0.75
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia. Core Evid (2005) 0.75
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time? Oncologist (2011) 0.75
Perturbation of the developmental potential of preimplantation mouse embryos by hydroxyurea. Int J Environ Res Public Health (2010) 0.75
The evidence-based analysis of treatment for chronic myeloid leukemia: An introduction to its methods and clinical implications. Blood (1999) 0.75
Chronic myeloid leukemia: reminiscences and dreams. Haematologica (2016) 0.75
The Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice. Endocrinology (2016) 0.75
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol (2017) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 9.70
The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum (1987) 9.24
The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum (1995) 7.97
Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med (2001) 7.94
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
"White-opaque transition": a second high-frequency switching system in Candida albicans. J Bacteriol (1987) 7.33
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood (1996) 7.31
Medical student selection: a tentative attempt to establish a code of practice. Br Med J (1980) 7.21
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Developing an evidence-based Guide to Community Preventive Services--methods. The Task Force on Community Preventive Services. Am J Prev Med (2000) 6.43
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Auditing audits: the method of Oxfordshire Medical Audit Advisory Group. BMJ (1991) 6.22
Clinical guidelines: developing guidelines. BMJ (1999) 6.01
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996) 5.45
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA (2001) 5.01
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Iatrogenic illness on a general medical service at a university hospital. N Engl J Med (1981) 4.82
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
The effects of recall on estimating annual nonfatal injury rates for children and adolescents. Am J Public Health (1994) 4.60
A simple, easy, and inexpensive method for monitoring ETCO2 through nasal cannulae. Anesthesiology (1987) 4.19
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
The relative role of "A" level chemistry, physics and biology in the medical course. Med Educ (1977) 3.89
Recognising clinical instability in hospital patients before cardiac arrest or unplanned admission to intensive care. A pilot study in a tertiary-care hospital. Med J Aust (1999) 3.76
Residential care for elderly people: a decade of change. BMJ (1993) 3.71
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Auditing audits: use and development of the Oxfordshire Medical Audit Advisory Group rating system. BMJ (1994) 3.64
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
An international study of the exposure of children to traffic. Inj Prev (1997) 3.55
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18
Examination of human stomach biopsies, saliva, and dental plaque for Campylobacter pylori. J Clin Microbiol (1989) 3.15
A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study. J Pediatr (1999) 3.03
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol (2008) 2.97
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst (1998) 2.96
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia (2009) 2.94
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Identification of a translation initiation factor 3 (eIF3) core complex, conserved in yeast and mammals, that interacts with eIF5. Mol Cell Biol (1998) 2.91
The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM (1998) 2.81
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia (2012) 2.80
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood (1999) 2.79
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet (2001) 2.76
Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell (2000) 2.75
T cell-dependent activation of resting B cells: requirement for both nonspecific unrestricted and antigen-specific Ia-restricted soluble factors. Proc Natl Acad Sci U S A (1981) 2.74
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia (2006) 2.66
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med (2001) 2.60
Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A (1998) 2.58
Occupational physical demands, knee bending, and knee osteoarthritis: results from the Framingham Study. J Rheumatol (1991) 2.56
RNA in human leukemic cells related to the RNA of a mouse leukemia virus (leukocytes-RNA-DNA hybridization-rauscher virus-polysomal RNA). Proc Natl Acad Sci U S A (1972) 2.55
Complex formation by all five homologues of mammalian translation initiation factor 3 subunits from yeast Saccharomyces cerevisiae. J Biol Chem (1998) 2.53
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
Small supernumerary marker chromosomes--progress towards a genotype-phenotype correlation. Cytogenet Genome Res (2006) 2.52
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52
Shared decision-making: the case for letting patients decide which choice is best. J Fam Pract (1997) 2.52
Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. Proc Natl Acad Sci U S A (1985) 2.50
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. J Clin Microbiol (1998) 2.47
Sickle cell "nondisease". A potentially serious public health problem. Am J Dis Child (1974) 2.46
Should we screen for prostate cancer? BMJ (1997) 2.43
Human leukaemic cells contain reverse transcriptase associated with a high molecular weight virus-related RNA. Nat New Biol (1972) 2.40
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia (2005) 2.38
Why do research on research? Lancet (1986) 2.36
Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. J Urol (1997) 2.32
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia (2002) 2.29
Purification and properties of virus particles, infectious subviral particles, and cores of bluetongue virus serotypes 1 and 4. Virology (1987) 2.27
Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. Science (1997) 2.27